home · filing · 0001619856-23-000134
8-K filed December 12, 2023, 6:59 PM ET
ticker CRBU
CIK 0001619856
regulatory
confidence high
sentiment positive
materiality 0.75
Caribou reaches FDA alignment on CB-010 phase 3 trial design; CMO to depart Dec 31
Caribou Biosciences, Inc.
FDA accepts comparator arm of platinum-based immunochemotherapy + HDCT + ASCT for CB-010 phase 3 in 2L r/r LBCL.
Phase 3 pivotal trial initiation planned by year-end 2024; RP2D and initial dose expansion data expected Q2 2024.
CB-010 is first allogeneic anti-CD19 CAR-T in 2L LBCL; granted RMAT, Fast Track, and Orphan Drug designations.
Chief Medical Officer Syed Rizvi to leave effective Dec 31, 2023; separation agreement with release required.
Search underway for new CMO; ANTLER dose expansion enrollment continues with 22 U.S. sites and 1 in Australia active.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2023-12-31
Filed December 12, 2023, 6:59 PM ET
Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Syed Rizvi departed as Chief Medical Officer at Caribou Biosciences, Inc..
Action leaving
Role Chief Medical Officer
Exact text from the filing
Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.
View on SEC.gov
Source: SEC EDGAR
accession 0001619856-23-000134
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.